EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer

Tadahiro Kuribayashi, Jun Nishimura, Sachi Okawa, Masataka Taoka, Shunta Mori, Takaaki Tanaka, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya, Go Makimoto, Kammei Rai und 6 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Tadahiro Kuribayashi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, O…. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Lung Neoplasms, Transforming Growth Factor beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy for epidermal growth factor receptor ( EGFR )‐mutated non‐small cell lung cancer (NSCLC) remains challenging. We previously found that EGFR‐tyrosine kinase inhibitors induced antitumor immunity but also triggered immunosuppressive cytokines, including transforming growth factor‐β (TGF‐β), in Egfr ‐mutant lung cancer. Here, we investigate whether TGF‐β inhibition potentiates osimertinib‐induced antitumor immunity using a syngeneic mouse model of Egfr ‐mutated lung cancer, with cancer cells subcutaneously transplanted into wild‐type C57BL/6J mice. We evaluated the antitumor effect of the combination therapy with osimertinib and either nintedanib (an indirect TGF‐β inhibitor) or vactosertib (a specific TGF‐β type I receptor kinase inhibitor). Changes in the tumor microenvironment during treatment were assessed using immunohistochemical staining, western blot analysis, and flow cytometry. We found that TGF‐β expression was upregulated in the tumor treated with osimertinib. Nintedanib monotherapy showed no significant antitumor effect, whereas osimertinib combined with nintedanib significantly potentiates the antitumor effect compared with osimertinib monotherapy in vivo. Crucially, no additive effect of nintedanib on osimertinib monotherapy was observed in vitro. Combination therapy with osimertinib and nintedanib significantly increased effector T cells (CD8 + CD44 + CD62L − ) and Granzyme B + areas and decreased CD206 + cells, while significantly decreasing TGF‐β and SMAD2/3 expression. Similar effects were observed with vactosertib but not with a vascular endothelial growth factor receptor 2 inhibitor. In conclusion, combination therapy with osimertinib and TGF‐β inhibitors potentiates osimertinib‐induced antitumor immunity. These findings highlight a novel therapeutic strategy for EGFR ‐mutated NSCLC and warrant further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsAcrylamidesLung NeoplasmsTransforming Growth Factor betaCarcinoma, Non-Small-Cell LungAnimalsPyrimidinesErbB ReceptorsIndolesMiceHumansMice, Inbred C57BLMutationCell Line, TumorTumor MicroenvironmentDrug SynergismProtein Kinase InhibitorsFemale

Stichwörter der Autor:innen

EGFRTGF‐βlung cancernintedanibosimertinib

Substanzen

Aniline CompoundsAcrylamidesosimertinibPyrimidinesErbB ReceptorsIndolesTransforming Growth Factor betanintedanibProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
  • Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.

ORCID-Profile: Eiki Ichihara, Katsuyuki Hotta, Yosuke Togashi, Kadoaki Ohashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Kuribayashi, T., Nishimura, J., Okawa, S., Taoka, M., Mori, S., Tanaka, T., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Rai, K., Ichihara, E., Hotta, K., Togashi, Y., Maeda, Y., Kiura, K., & Ohashi, K. (2026). TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70352

Vancouver

Kuribayashi T, Nishimura J, Okawa S, Taoka M, Mori S, Tanaka T, et al. TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer. Cancer Science. 2026. doi:10.1111/cas.70352

BibTeX
@article{Kuribayashi2026,
  author = {Kuribayashi, Tadahiro and Nishimura, Jun and Okawa, Sachi and Taoka, Masataka and Mori, Shunta and Tanaka, Takaaki and Nishimura, Tomoka and Morita, Ayako and Hara, Naofumi and Ninomiya, Kiichiro and Makimoto, Go and Rai, Kammei and Ichihara, Eiki and Hotta, Katsuyuki and Togashi, Yosuke and Maeda, Yoshinobu and Kiura, Katsuyuki and Ohashi, Kadoaki},
  title = {TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70352}
}
Kostenlos starten →